Phase I Dose-Escalation Study of Venetoclax Plus Beam Followed by Autologous Stem Cell Transplant (Asct) for Chemoresistant, Relapsed/Refractory, or High-Risk Non-Hodgkin's Lymphoma (Nhl); Preliminary Results

Hematological Oncology - United Kingdom
doi 10.1002/hon.213_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients With Non-Hodgkin's Lymphoma (NHL)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study

Bone Marrow Transplantation
TransplantationHematology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy